title: New Observer-Reported Outcomes To Measure Treatment Satisfaction, Compliance, Palatability, and Gi Symptoms for Patients Needing Iron-Chelation Therapy.
authors.affiliation: Pharmerit International, Cambridge, MA, USA.
authors.forename: K
authors.initials: K
authors.lastname: Lasch
authors.affiliation: Pharmerit International, Bethesda, MD, USA.
authors.forename: E G
authors.initials: EG
authors.lastname: Horodniceanu
authors.affiliation: Pharmerit International, Bethesda, MD, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Carter
authors.affiliation: Pharmerit International, Bethesda, MD, USA.
authors.forename: H
authors.initials: H
authors.lastname: Dhatt
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: V
authors.initials: V
authors.lastname: Bal
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: I
authors.initials: I
authors.lastname: Côté
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: N
authors.initials: N
authors.lastname: Constantinovici
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: R M
authors.initials: RM
authors.lastname: Herranz
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: I
authors.initials: I
authors.lastname: Malet